Anagenxyz, a telehealth platform specializing in hair growth, has announced significant advancements in its treatment offerings, including the repurposing of Liothyronine (T3) for hair loss and the launch of a new "Precision Dutasteride" formulation. The developments were highlighted by Dr. Shelby, a partner at CompoundVC, in a recent social media post, emphasizing the company's progress driven by community coordination and rapid human evidence.
"We discuss what our portfolio company @anagenxyz has accomplished in its short history. A big part of their progress is from community coordination and rapid human evidence," Dr. Shelby stated in the tweet.
Among the key innovations, Anagenxyz has introduced a novel hormonal hair loss drug by repurposing Liothyronine (T3). This marks the first time in 30 years that T3 has been brought to market for this indication, leveraging its role in hair follicle cycling. The company's blog further notes that preclinical research and observational studies suggest low-dose topical T3 could be a valuable addition for individuals experiencing thinning hair.
The company has also reformulated and launched "Precision Dutasteride," designed to achieve hair regrowth with potentially fewer side effects. Traditional dutasteride, a potent 5α-reductase inhibitor, faces challenges in topical application due to systemic absorption. Anagenxyz's extensive research focused on optimizing delivery to the hair follicle while minimizing bloodstream entry, achieving a follicular targeting factor of 0.6—two to three times higher than standard topical formulations.
Additionally, Anagenxyz has launched a slow-release minoxidil drug and built a comprehensive knowledge base with proprietary hair follicle data. These offerings are integrated into their telehealth platform, providing personalized, science-led treatments. The hair loss market is substantial, affecting an estimated 80 million individuals in the U.S. alone, positioning Anagenxyz's targeted and innovative approaches to address a significant unmet need.
